DexCom, Inc. DXCM
86.62
(0.85)
(0.97%)
as of 25 Sep
- Market cap
- $33.0B
- P/E
- 33.4×
Follow DXCM
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
DexCom, Inc. (DXCM) Net margin
DexCom, Inc.'s net margin over the twelve months to 30 June 2026 was 20.1%, up 2.2 percentage points from fiscal 2025 (17.9%). Over the past ten years it has ranged from −14.3% (fiscal 2015) to 28.5% (fiscal 2020); the current reading is higher than 91% of that period. That is above the Medical Devices industry median of −20.4% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 17.9% | 3.65 |
| FY2024 | 14.3% | (0.66) |
| FY2023 | 15.0% | 3.22 |
| FY2022 | 11.7% | 2.87 |
| FY2021 | 8.86% | (19.67) |
| FY2020 | 28.5% | 21.68 |
| FY2019 | 6.85% | 19.17 |
| FY2018 | −12.3% | (5.33) |
| FY2017 | −6.99% | 4.45 |
| FY2016 | −11.4% | 2.89 |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 19.0% | 2.30 |
| Mar 2026 | 16.7% | (4.48) |
| Dec 2025 | 21.2% | (2.25) |
| Sep 2025 | 23.5% | 7.93 |
| 42 more quarters | Free account |
Against its own ten years
Low −14.3%
High 28.5%
Ten-year median
8.86%
Current reading's percentile
91
Net margin against peers
| Company | Net margin |
|---|---|
| DXCM DexCom, Inc. | 20.1% |
| BSX Boston Scientific Corporation compare | 17.5% |
| EW Edwards Lifesciences Corporation compare | 15.4% |
| STE STERIS plc compare | 13.3% |
| PEN Penumbra, Inc. compare | 10.7% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 9.48% |
| GEHC GE HealthCare Technologies Inc. compare | 9.33% |
| SNN Smith & Nephew SNATS, Inc. compare | 6.71% |
| PHG Koninklijke Philips N.V. compare | 6.24% |
| Medical Devices industry median | −20.4% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on DXCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement